Suppr超能文献

巨噬细胞疗法治疗小鼠肝纤维化可募集宿主效应细胞,改善纤维化、再生和功能。

Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.

机构信息

MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK.

出版信息

Hepatology. 2011 Jun;53(6):2003-15. doi: 10.1002/hep.24315.

Abstract

UNLABELLED

Clinical studies of bone marrow (BM) cell therapy for liver cirrhosis are under way but the mechanisms of benefit remain undefined. Cells of the monocyte-macrophage lineage have key roles in the development and resolution of liver fibrosis. Therefore, we tested the therapeutic effects of these cells on murine liver fibrosis. Advanced liver fibrosis was induced in female mice by chronic administration of carbon tetrachloride. Unmanipulated, syngeneic macrophages, their specific BM precursors, or unfractionated BM cells were delivered during liver injury. Mediators of inflammation, fibrosis, and regeneration were measured. Donor cells were tracked by sex-mismatch and green fluorescent protein expression. BM-derived macrophage (BMM) delivery resulted in early chemokine up-regulation with hepatic recruitment of endogenous macrophages and neutrophils. These cells delivered matrix metalloproteinases-13 and -9, respectively, into the hepatic scar. The effector cell infiltrate was accompanied by increased levels of the antiinflammatory cytokine interleukin 10. A reduction in hepatic myofibroblasts was followed by reduced fibrosis detected 4 weeks after macrophage infusion. Serum albumin levels were elevated at this time. Up- regulation of the liver progenitor cell mitogen tumor necrosis factor-like weak inducer of apoptosis (TWEAK) preceded expansion of the progenitor cell compartment. Increased expression of colony stimulating factor-1, insulin-like growth factor-1, and vascular endothelial growth factor also followed BMM delivery. In contrast to the effects of differentiated macrophages, liver fibrosis was not significantly altered by the application of macrophage precursors and was exacerbated by whole BM.

CONCLUSION

Macrophage cell therapy improves clinically relevant parameters in experimental chronic liver injury. Paracrine signaling to endogenous cells amplifies the effect. The benefits from this single, defined cell type suggest clinical potential.

摘要

未标注

骨髓(BM)细胞疗法治疗肝硬化的临床研究正在进行中,但获益机制仍未确定。单核细胞-巨噬细胞系的细胞在肝纤维化的发生和消退中起关键作用。因此,我们测试了这些细胞对小鼠肝纤维化的治疗效果。通过慢性四氯化碳给药在雌性小鼠中诱导晚期肝纤维化。在肝损伤期间,给予未经处理的同种异体巨噬细胞、其特定的 BM 前体或未分离的 BM 细胞。测量炎症、纤维化和再生的介质。通过性别不匹配和绿色荧光蛋白表达来追踪供体细胞。BM 衍生的巨噬细胞(BMM)的递送导致趋化因子的早期上调,伴有内源性巨噬细胞和中性粒细胞向肝脏募集。这些细胞分别将基质金属蛋白酶-13 和 -9 递送至肝瘢痕中。效应细胞浸润伴随着抗炎细胞因子白细胞介素 10 水平的升高。巨噬细胞输注后 4 周,肝肌成纤维细胞减少,纤维化减少。此时血清白蛋白水平升高。肝祖细胞有丝分裂原肿瘤坏死因子样弱凋亡诱导剂(TWEAK)的上调先于祖细胞区室的扩张。集落刺激因子-1、胰岛素样生长因子-1 和血管内皮生长因子的表达增加也紧随 BMM 递送之后。与分化巨噬细胞的作用相反,巨噬细胞前体的应用并未显著改变肝纤维化,并且整个 BM 的应用加剧了肝纤维化。

结论

巨噬细胞细胞疗法改善实验性慢性肝损伤的临床相关参数。旁分泌信号转导至内源性细胞可放大作用。单一明确的细胞类型的益处表明具有临床潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验